Codiak BioSciences, Inc. Cash and Cash Equivalents
Codiak BioSciences, Inc. had Cash and Cash Equivalents of $51.76 million as of 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2022-11-03
- 2022-09-30: Cash and Cash Equivalents, at Carrying Value $51.76M.
- 2022-06-30: Cash and Cash Equivalents, at Carrying Value $41.78M.
- 2022-03-31: Cash and Cash Equivalents, at Carrying Value $56.49M.
- 2021-12-31: Cash and Cash Equivalents, at Carrying Value $76.94M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2022-09-30 | $51.76M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $41.78M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $56.49M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $76.94M 10-Q · filed 2022-11-03 |
| 2021-09-30 | $98.58M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $113.68M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $130.27M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $88.92M 10-K · filed 2022-03-10 |
| 2020-09-30 | $48.34M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $50.95M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $47.84M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $10.32M 10-K · filed 2021-03-17 |
| 2019-09-30 | $32.06M 10-Q · filed 2020-11-19 |